Scientific Articlesby Voluntary Organization JBCRG
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young-Hyuck Im, Eun-Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim, Yasuhiro Yanagita, Shinji Ohno, Shintaro Takao, Kenjiro Aogi, Hiroji Iwata, Joon Jeong, Aeree Kim, Kyong-Hwa Park, Hironobu Sasano, Yasuo Ohashi, and Masakazu Toi.
The New England Journal oｆ Medicine 2017; 376:2147-2159 June 1, 2017DOI: 10.1056/NEJMoa1612645
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young-Hyuck Im, Eun-Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim, Yasuhiro Yanagita, Shinji Ohno, Shintaro Takao, Kenjiro Aogi, Hiroji Iwata, Joon Jeong, Aeree Kim, Kyong-Hwa Park, Hironobu Sasano, Yasuo Ohashi, and Masakazu Toi.
The New England Journal oｆ Medicine 2017; 376:2147-2159 June 1, 2017DOI: 10.1056/NEJMoa1612645
Comparison of different definitions of pathologic complete response in operable breast cancer; a pooled analysis of three prospective neoadjuvant studies of JBCRG
Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F.
Breast Cancer 2015 Nov;22(6):586-95.
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer.
Kuroi K,. Toi M, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG).
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S387-92.
Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients With Primary Breast Cancer
Hiroji Iwata, Nobuaki Sato, Norikazu Masuda, Seigo Nakamura, Naohito Yamamoto, Katsumasa Kuroi, Masafumi Kurosumi, Hitoshi Tsuda, Futoshi Akiyama, Yasuo Ohashi, and Masakazu Toi
Japanese Journal of Clinical Oncology 41: 867-875, 2011
PhaseII study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, YamazakiK, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F,Ohashi Y, Takatsuka Y; for Japan Breast Cancer Research Group (JBCRG)
Breast Cancer Res Treat. 2008 Aug;110(3):531-9. Epub 2007 Sep 19
Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG).
Breast Cancer. 2005; 13(1): 38-48.
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer.
Kuroi K,. Toi M, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG).
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S387-92.
Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer
Ohno S, Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, Masuda N, Yamazaki K, Hisamatsu K, Sato Y, Takatsuka Y, Shin E, Kaise H, Kurozumi M, Tsuda H, Akiyama F; Japan Breast Cancer Research Group (JBCRG).
Biomed Pharmacother.2005 Oct;59 Suppl 2:S323-4.
Interim analysis of a phaseII trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breastcarcinoma
Iwata H, Nakamura S, Toi M, Shin E, Masuda N, Ohno S, Takatsuka Y,Hisamatsu K, Yamazaki K, Kusama M, Kaise H, Sato Y, Kuroi K, Akiyama F, Tsuda H, Kurosumi M; Japan Breast Cancer Research Group (JBCRG).
Breast Cancer. 2005;12(2):99-103.